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A B S T R A C T   
Metagenomic high-throughput sequencing (mHTS) is a hypothesis-free, universal pathogen detection technique 
for determination of the DNA/RNA sequences in a variety of sample types and infectious syndromes. mHTS is still 
in its early stages of translating into clinical application. To support the development, implementation and 
standardization of mHTS procedures for virus diagnostics, the European Society for Clinical Virology (ESCV) 
Network on Next-Generation Sequencing (ENNGS) has been established. The aim of ENNGS is to bring together 
professionals involved in mHTS for viral diagnostics to share methodologies and experiences, and to develop 
application recommendations. This manuscript aims to provide practical recommendations for the wet lab 
procedures necessary for implementation of mHTS for virus diagnostics and to give recommendations for 
development and validation of laboratory methods, including mHTS quality assurance, control and quality 
assessment protocols.   
1. Introduction 
Metagenomic high-throughput sequencing (mHTS) is a hypothesis- 
free, universal pathogen detection technique for the determination of 
DNA/RNA sequences in a variety of clinical sample types and infectious 
syndromes. mHTS provides the most comprehensive untargeted 
approach for the detection of all viruses in a single assay. This approach 
is suited for identification of any viral pathogen, but particularly for: (i) 
distinguishing viruses with similar symptom profiles that, in a classic 
diagnostic laboratory, would therefore require a high number of tar-
geted molecular single-plex assays, (ii) identifying pathogens that not 
have been associated with a particular symptom profile before, such as 
astrovirus encephalitis; (iii) discovering novel pathogens which would 
remain undetectable by target-based methods [1,2]; and (iv) accurate 
detection and study of RNA viruses with high levels of genetic diversity 
and therefor often refractory to reliable target-specific diagnostics. 
Recently, it has been shown that mHTS workflows allow for identi-
fication of pathogens within a clinically relevant timeframe [3]. 
Furthermore, mHTS allows the simultaneous characterization of com-
plete genome sequences, virulence factors, resistance and epidemio-
logical markers [4]. Despite these clear advantages, mHTS is still in its 
early stages of translation into clinical application. The current clinical 
applications of mHTS have focused on patients with encephalitis [5], 
while research applications are much more common. These include the 
recent rapid and impactful metagenomic analysis of SARS-CoV-2 [2]. 
One of the challenges in clinical use of mHTS is the current lack of 
standardization of mHTS to ensure sensitive and specific pathogen 
detection. The development of guidelines and recommendations on 
mHTS methods and workflows will assist the implementation of mHTS 
in diagnostic laboratories, ensuring the validity of results that will affect 
patient management. 
To support the development and implementation of mHTS proced-
ures for virus diagnostics, a network has been established under the 
auspices of the European Society for Clinical Virology (ESCV): the ESCV 
Network on Next-Generation Sequencing (ENNGS). The aim of this 
network is to bring together professionals involved in mHTS for viral 
diagnostics and to share methodologies and experiences, and to develop 
recommendations for the use of mHTS in clinical laboratories. 
2. Aim and scope 
This review aims to give recommendations for the implementation 
and validation of laboratory methods for viral mHTS, including quality 
control (QC) and quality assessment (QA) protocols, but excluding the 
bioinformatic part of the process, which warrants separate discussion 
(Part II) outside the scope of the current review. We aim to provide 
practical recommendations for the pre-analytic and analytic steps for 
successful implementation of mHTS procedures in viral diagnostic 
laboratories. 
3. Recommendations 
3.1. Facility requirements and equipment 
3.1.1. Organization of laboratory space 
Organization of laboratory space and the diagnostic workflow are 
vital for the implementation of mHTS due to the unbiased nature of 
mHTS and the associated increased risk of detection and thus interfer-
ence of cross-contaminants [6,7]. A common mHTS wet lab workflow 
consists of five steps, i) reagent preparation, ii) sample preparation and 
nucleic acid extraction, iii) mHTS library preparation, iv) PCR amplifi-
cation of the library (adapter extension), and v) product analysis and 
sequencing (Fig. 1). Additional enrichment procedures may be intro-
duced before and after library preparation. Special emphasis with regard 
to the risk of cross-contamination in mHTS lies on the steps before 
adapter ligation. A separate preparation area and lab equipment (e.g. 
pipettes) is required for diagnostic mNGS and workflows that involve 
high titre pathogens, such as cultivated and PCR-preamplified samples 
(e.g. for typing) (Recommendations 1–4, Table 1). Separate laboratory 
spaces for mHTS sample processing may be considered, including a 
safety cabinet with exclusive use for mHTS. 
3.1.2. NGS instruments: use of local and core facilities 
mHTS is usually performed on medium and high output platforms, 
such as the Illumina MiSeq, NextSeq, HiSeq, Novaseq, and Ion S5 
(Table 2) systems due to the high number of reads required (>10 million 
reads per sample) given the generally low proportion of viral reads in 
clinical samples [8,9]. HTS equipment with smaller sequencing capac-
ity, such as the iSeq, MiniSeq, and MinION [10] are generally used for 
targeted genomic analysis of a small number of samples, selected mi-
croorganisms and fieldwork [11] (Recommendations 5-6). Mid-size 
sequencers like the MiSeq and Ion S5 systems offer the advantage of 
more frequent runs with only a few samples, however, at higher cost. To 
make efficient use of high-throughput sequencing instruments within 
reasonable turn-around-time a shared use with other diagnostic pur-
poses, i.e. molecular pathology or haematology, may be considered. 
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One option for smaller clinical laboratories is to outsource (parts of) 
the mHTS workflow to a third-party service provider. Outsourcing of 
parts of the process may be carefully considered with attention to 
quality, safety, transparency, and flexibility in case of desired adapta-
tions of the protocol (Recommendation 7). Given the contamination 
issues relating to sample preparation for mHTS, separation of mHTS 
preps from other library preps performed at third-party providers should 
be warranted and attention should be paid to carry-over from other 
samples and runs. Index hopping: misassignment of barcodes between 
multiplexed Illumina libraries can occur in proportions relevant for 
pathogen detection even with dual indexing, and this risk should be 
managed. 
Examples of commercial providers for mHTS with and without 
analysis pipelines are listed in Table 3. Distinction is made between 
providers of full mHTS service (sample-to-result), commercial kits 
including analysis software for use in local laboratories, outsourcing of 
sequencing, and outsourcing of bioinformatic analysis (Part II). Specific 
attention should be payed to the management and storage of human 
genomic sequences by third parties, which should be in line with (inter) 
national regulations. 
4. Assay design and development 
4.1. Nucleic acid (NA) extraction 
The optimal method for NA isolation from clinical samples for mHTS 
is dependent on the sample type and can be different from those opti-
mized for PCR. DNA and RNA can be co-extracted or isolated separately, 
and the suitable method should be validated separately for each aim 
(Recommendation 8). For example, while total NA extraction and RNA 
extraction methods preceding PCR commonly result in comparable 
quantification cycle (Cq) values in real-time PCR, sequencing of total NA 
generally results in lower coverage of RNA virus genomes compared to 
sequencing of samples extracted using specific RNA extraction methods 
[12]. RNA can be also be obtained by DNase treatment of total NA. The 
use of high concentrations of carrier RNA should be avoided for RNA 
mHTS (Recommendation 9) as it will be sequenced along with the 
sample RNA, and thus may affect the ability to detect low level 
pathogens. 
4.2. Host NA depletion and viral enrichment 
The paucity of viral NA among the rich background of other se-
quences may necessitate depletion of host (or bacterial) sequences and/ 
or enrichment of viral sequences either i) prior to NA extraction (pre- 
extraction), by removing whole cells or purifying viral particles, or ii) 
after extraction, on NA (post-extraction). In general, depletion and 
enrichment protocols affect the unbiased nature of the approach and 
increase the risk of selective exclusion of (specific) viral sequences. 
i) Pre-extraction, depletion of whole human cells can be achieved by 
centrifugation to pellet human cells, filtration to remove human and 
bacterial cells, treatment of intact cells with a surfactant like saponin 
[13], cell lysis followed by propidium monoazide treatment [14], or 
nuclease treatment to remove free non-encapsulated RNA and DNA from 
the sample. However, pre-extraction depletion of host cells has been 
reported to be disadvantageous in clinical samples, given the exclusion 
of intracellular viral particles or NA [15]. For example, more reads from 
respiratory viruses were found in respiratory samples without enrich-
ment as compared to virus enrichment by cellular filtration [16]. 
Moreover, pre-extraction viral enrichment protocols are not easily 
automated and negatively affect the turn-around-time. Instead, the 
number of specific sequences obtained from clinical samples with low 
non-enriched target virus concentration can be increased by increasing 
the number of total sequence reads per sample and such protocols 
without complicated sample pretreatment can be automated [8]. 
ii) Post-extraction; host NA depletion can be achieved by selective 
removal of CpG methylated sequences or selective methylation- 
dependent cleavage of DNA [17] for DNA mHTS, and, by removal of 
ribosomal RNA of human or bacterial origin, for RNA mHTS. CpG se-
quences of certain DNA viruses can be methylated, but almost exclu-
sively during latency when integrated in the human genome (e.g. 
adenoviruses, gammaherpesviruses, papillomaviruses, polyomaviruses) 
[18]. Removal of ribosomal RNA preceding transcriptome sequencing is 
commonly performed by poly(A)-mRNA selection. The mRNA of 
eukaryotic viruses is usually poly(A) tailed, in addition to the genomic 
template of some viruses (e.g. picornaviruses) [19,20]. Some viruses 
Fig. 1. Schematic overview of the unidirectional workflow of molecular diagnostics including the recommendations for mHTS. NA; nucleic acid.  
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initiate translation in the absence of poly(A) tail by using functional 
analogues (e.g. hepatitis C viruses, rotaviruses [21,22]) and 
non-replicative viruses may be missed when using this type of selection 
method. Alternative methods for removal of ribosomal RNA are hy-
bridization to ribosomal oligo probes, and targeted amplification by 
using ‘random’ hexamer primers with a decreased affinity for rRNA 
during first strand cDNA synthesis (see below). 
Metagenomic libraries can also be enriched for viral sequences after 
extraction and reverse transcription steps with capture probe enrich-
ment methods, which are based on hybridisation to a wide set of se-
quences specific for one or all known vertebrate viruses [23,24]. This 
strategy may distort the ratios between viruses, but will allow for 
detection of novel viruses up to a certain degree of nucleotide identity 
[1]. The significant improvement in sensitivity [23–25] is an advantage 
for application in clinical virus diagnostics (Recommendation 10). 
4.3. Double-stranded cDNA synthesis 
Viral metagenomics is exceptional among HTS approaches in that the 
targeted genomes consist of both DNA and RNA. To this end, extracted 
NA are usually processed separately to generate specific DNA and RNA 
libraries. Current commercial DNA and RNA library preparation kits 
require two ends of double-stranded DNA in order to ligate adapters by 
T4 DNA ligase or transposase. Recently, protocols for direct RNA 
sequencing of viral RNA have been developed using the Oxford Nano-
pore Technologies [26]. Double-stranded DNA is usually synthesized 
using random primers in two subsequent steps: the first and second 
strand synthesis. As described above, reduction of cDNA synthesis of 
ribosomal RNA can, at this stage, be achieved by using hexamer primers 
with reduced affinity for ribosomal RNA [27]. 
Subsequent procedures to enrich the synthesized double-stranded 
DNA such as sequence-independent, single-primer amplification 
(SISPA) [28] and multiple displacement amplification (MDA) using 
high-fidelity Phi29 polymerase are prone to selective, biased amplifi-
cation [29]. This unusually high degree of amplification (>30 cycles) of 
the source material may result in distortion of the viral population ratios 
and quantitative comparison of viral species. To prevent selective 
amplification or bias resulting in possible overrepresentation of certain 
viruses, SISPA and MDA are not recommended for comparison of viral 
population proportions [30] (Recommendation 11). Enrichment for 
specific viral targets using spiked primers during reverse transcription 
has been suggested to increase sensitivity, although this method is also 
biased [31]. 
4.4. Sequencing library preparation 
There are two major strategies for generating sequencing libraries: i) 
“tagmentation” where enzymatic fragmentation of dsDNA and ligation 
of adaptors are performed simultaneously (Nextera XT workflow by 
Illumina) or sequentially (VIDISCA-NGS [32]), and ii) physical 
Table 1 







1 Physical separation of reagent preparation, pre- 
amplification and post-amplification library 
preparation.  
2 Dedicated materials and reagents for each process 
(sample processing, library preparation, post-library 
preparation).  
3 Physical separation of metagenomic library 
preparation from sample preparation of series of 
positive samples (e.g. for typing), e.g. by using a 
dedicated biosafety cabinet (BSC) with restricted use 
for metagenomic workflows.  
4 Extensive cleaning of materials and surfaces with 10% 
sodium hypochlorite and/or ammonium compound 
before and after processing, more frequently than 
regularly performed for molecular assays. 
HTS platform (3.1.2)  5 Choice depending on the application and intended use 
(metagenomics, whole genome sequencing, 
fieldwork).  
6 Restrict low output sequencers use for a limited 
number of specimens (due to their lower throughput 
and multiplexing and deep sequencing capacity).  
7 Consider the number of samples per run in relation 
with batch-wise sequencing and consequences for turn- 
around-time. Outsourcing of parts of the process may 
be carefully considered with attention to quality, 
safety, transparency and flexibility to desired adapta-
tions of the protocol. 
Assay design and 
development (4) 
8 DNA and RNA can be co-extracted or isolated sepa-
rately, with impact on the mHTS results (sensitivity, 
coverage), and separate protocols should be validated 
individually.  
9 Avoid the use of high concentrations of carrier RNA 
during extraction for RNA mHTS.  
10 Advantages of target enrichment should be weighed 
against the potential bias introduced by the specific 
protocol.  
11 SISPA and MDA should not be used when performing 
viral metagenomics aiming at quantification of viral 
species, since this may result in over- and 
underrepresentation of the true proportions for 
certain viruses.  
12 The minimum number of post-ligation amplification 
cycles should be used, in order to minimize amplifi-
cation bias.  
13 The library size distribution should be checked for the 
expected fragment size, to discard degraded libraries 
(excess short fragments) or incomplete fragmentation 
(excess long fragments). Accurate library 
quantitation ensures adequate library pooling in the 
sequencing run.  
14 A no-template control that will undergo all steps from 
sample extraction to sequencing should be used in 
every individual sequencing run.  
15 More upfront negative controls are recommended to 
identify sources of potential contamination, such as a 
library preparation buffer and a pathogen-negative 
sequence controls (e.g. phage lambda prepared with 
different reagents).  
16 To control for the success of NA extraction, 
preparation and sequencing, clinical samples should 
be spiked with encapsidated RNA or DNA viruses that 
do not infect humans (vertebrates), e.g. 
bacteriophages. 
Validation & 
accreditation (5, 6)  
17 The following wet lab parameters in the validation 
process should be included in the validation: sample 
type, sample volume, extraction protocol, library 
preperation protocol.  
18 The following sequencing parameters should be 
included in the validation process: precision, 
accuracy of sequence output, sequence depth, 
analytical sensitivity, specificity, limit of detection.  




19 Result interpretation: a cut-off for defining a positive 
result (read count, coverage) should be determined 
based on validation data, e.g. comparison with PCR 
results, using prototype viruses. For defining a posi-
tive result, use a threshold of three distinctly covered 
genome regions after background subtraction based 
on negative controls.  
20 An external quality assessment programs (EQA) 
should be adhered to evaluate the performance of 
metagenomics protocols applied in diagnostic 
settings, assessing both qualitative (correct pathogen 
detection) and quantitative characteristics (target 
read numbers).  
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(mechanical or biochemical) shearing followed by DNA fragment end 
polishing, A-tailing, and finally ligation tagging have been implemented 
by several workflows. For low-abundance clinical samples, amplifica-
tion after adapter ligation (12–16 cycles) is needed. Quantitative bias is 
introduced during post-ligation amplification [33] and even though the 
clinical implications for qualitative virus detection remain uncertain, it 
is recommended not to increase the number of post-ligation amplifica-
tion cycles (Recommendation 12). Recently, a number of commercial 
library kits have become available supporting very low DNA input (as 
low as 1− 5 ng). 
The prepared libraries are checked for integrity, size distribution and 
quantity, and equalized in order to provide comparable counts of total 
reads per sample during sequencing. It must be noted that this will not 
result in comparable counts of viral reads given the differences in human 
and bacterial background reads. Deciding whether or not to sequence a 
library is a critical step and can change the time to results by a couple of 
days if a poor quality library is initially sequenced. Important parame-
ters to assess good library quality for clinical testing include library size 
and concentration, measured by fragment analyzers and/or qPCR. The 
library size distribution should be checked for ideally a single peak 
around the expected fragment size, to discard degraded libraries or 
incomplete fragmentation. Accurate library quantitation is fundamental 
to normalise library pooling in the sequencing run (Recommendation 
13). 
4.5. Quality controls 
Since mHTS will allow the detection of NA contamination from re-
agents used in sample treatment, library preparation, and sequencing 
[34–36], a no-template control that will undergo all steps of the work-
flow in parallel to the sample needs to be included in every individual 
sequencing run (Recommendation 14). This so-called “kitome control” 
can be used to eliminate the contaminating reads from the patient 
samples, either manually or by means of automated scripts such as 
Recentrifuge [37] or Decontam [38]. The use of other upfront negative 
controls is also recommended to identify sources of potential contami-
nation, such as a library preparation buffer and a pathogen-negative 
sequence control (e.g. phage lambda prepared with other reagents 
than the patient sample) (Recommendation 15). The use of 
pathogen-negative human samples as negative controls is less recom-
mended given the variability in human background genome per sample 
and type of material. 
To control the success of NA isolation, library preparation and 
sequencing in routine diagnostics, spiking of clinical samples with 
encapsidated RNA and DNA viruses that are not found in humans 
(vertebrates) are recommended, such as baculoviruses, phocine 
herpesvirus; tobacco mosaic virus, phages with DNA or RNA genome 
(MS2 coliphage, Enterobacteria phage T1) [39], or virus-like particles 
containing non-infectious NA, i.e. Armored RNA (Ambion, Asuragen) 
(Recommendation 16). The amount of internal control added should 
be optimized to avoid either dropout or competition with pathogenic 
sequences [40]. The amount of host RNA and DNA will affect the 
amount of internal control reads, and thus a sharp acceptance threshold 
is difficult to determine. However, because of this variability, the pro-
portion of internal control reads detected in a clinical sample can be 
used to normalise viral loads in mHTS quantitative algorithms [41]. To 
keep track of the performance of the metagenomic workflow over time, 
an external positive control panel is recommended periodically. 
5. Assay validation 
At present it is unclear how mHTS will fit into the new European 
Union (EU) In Vitro Devices Regulation (IVDR), since further guidance 
on the interpretation of how laboratory-developed tests (LDTs) are 
regulated is required (https://eur-lex.europa.eu/legal-content/EN/TX 
T/?uri=CELEX:02017R0745-20170505, www.euivdr.com/). Practice- 
based guidelines and validation studies on mHTS technologies have 
been recently published in the fields of oncology [42], and broad 
pathogen detection [40,43]. Many points regarding these requirements 
are generally applicable for viral mHTS, including the laboratory and 
data analysis processes. A comprehensive set of recommendations for 
validation of viral mHTS assays are summarized here (Recommenda-
tions 17–20): 
Optimal sample volume. Clinical pathogen mHTS protocols in place 
regularly use 200–600 ųL for serum, plasma, CSF or BAL [5,8,30,40,41, 
44–46]. The used sample volume is one of the factors determining the 
limit of detection of the mHTS assay, and a higher sample volume is 
desirable if available, but avoiding excess human reads. 
Reference materials. The detection of a wide range of diverse viruses 
(DNA/RNA, different genome size, double and single stranded, linear 
and circular, enveloped/non-enveloped) should be analyzed when 
validating a viral mHTS protocol. In the absence of virus positive re-
sidual clinical material, mock samples in the relevant matrix can be 
made “in-house” using reference material or obtained commercially 
[47], for instance from the European virus archive (www.european-vir 
usarchive.com), UK-NIBSC (www.nibsc.org), ATCC (www.lgcstandards 
-atcc.org), Vircell (www.vircell.com), viral multiplex controls (www. 
nibsc.org/documents/ifu/15− 130-xxx.pdf) or a virome mix (www.lgcs 
tandards-atcc.org/products/all/MSA-2008.aspx), available from 
UK-NIBSC or ATCC (www.lgcstandards-atcc.org/pro-
ducts/all/MSA-4000.aspx). Reference control material should ideally 
include multiple viruses with known relative loads to monitor speci-
ficity, or separate mixtures with high and low viral concentration to 
monitor sensitivity. 
Precision (repeatability, reproducibility). Replicates (intra-assay) 
and repeats (inter-assay) of aliquoted clinical samples or spiked 
Table 2 
Main features of current HTS sequencing platforms and most common applications in virology.  
Instrument Av. read length Final Error Rate 
(%) 







Illumina benchtop small scale (iSeq, MiniSeq) 2 × 150− 2 × 300 
bp 
~0.1 1.2 – 7.5 4 -55 $100 - 
$600 
WGS, AVR, quasi-species 
Illumina medium and large scale (MiSeq, HiSeq, 
NovaSeq) 
2 × 150 bp ~0.1 15 – 6000 12 -144 $7 - $50 Batched samples 
Metagenomics 
Ion Torrent (Proton, S5) 150 bp ~1 1 – 25 2–4 $20 - $80 Rapid runs, WGS 
S5: metagenomics 
PacBio RSII 20 Kb ~1 0.5 - 1 4 $400 Complete SMS genomes 
PacBio Sequel II (HiFi, circular mode) >50 Kb (9− 13 Kb) 
~1 
160 0.5− 6 $45 Complete SMS genomes ~0.1 
Oxford Nanopore 
>200 Kb 2− 13 30 1 min-72 $15 - $60 Real-time testing, in field 
MinIon (R9-R10) 
Oxford Nanopore 
>200 Kb 2− 13 150 1 min-72 $3 - $20 Simultaneous real-time 
testing GridIon (R9-R10) 
WGS; whole genome sequencing, AVR; antiviral resistance, SMS; single molecule sequencing. 
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(internal/mock) controls should be sequenced overtime to test for assay 
repeatability and reproducibility throughout the entire mHTS workflow. 
Sample replicates and repeats may include one DNA and one RNA virus 
(with known concentration or a dilution series), or multiple viruses 
combined. A virus negative sample should be included. Finally, a 
number of 20 mHTS runs has been recently used to monitor for changes 
before assay implementation [47] (Recommendation 18). 
Accuracy of sequence output. Sequencing errors and (RT-)PCR 
induced errors might not compromise the identification of an infectious 
agent but they can compromise the identification of specific mutations 
that code for resistance, virulence or transmissibility, especially within 
quasispecies [48]. When looking for mutations (i.e. antiviral drug 
resistance), it is useful to assess the introduction of NA amplification and 
sequencing errors during the HTS process by validating reference ma-
terials: well characterized homogenous NA (plasmids including viral 
inserts, replicons, viral RNA transcripts [49] or Unique Molecular 
Identifiers) to determine a threshold for the identification of “true” 
mutations. Bioinformatic scripts can be helpful to reduce (RT-)PCR 
induced errors from (m)HTS datasets [50–53], and to adapt correction 
to the different inherent error rates for each platform. For newest 
technologies with higher error rates, such as nanopore, including closely 
related viruses during validation can control assay performance to 
distinguish particular species from background noise. 
Sequencing depth and coverage. Sufficient sequencing depth is 
important to ensure reliable detection of low-abundancy pathogens and 
low-frequency variants. The acquired depth depends mainly on the 
sequencing platform in combination with run-time, but also on library 
preparation, target enrichment and the expected sequence complexity 
and on the amount of background (human or bacterial) NA and the 
degree of multiplexing. The required minimum depth is variable per 
protocol and should be tested for each sample type during the validation 
stage. For antiviral drug resistance it is recommended that a given 
mutation is detected with a 1,000x coverage depth, although this de-
pends on the intrinsic error rate of the sequencing platform used. 
For virus detection by mHTS, low horizontal coverage of the genome 
length but with reads distributed over the genome can represent true 
positive findings [25], whereas a large number of reads (high coverage 
depth) aligned at one specific part of the genome can represent a false 
positive result, or novel far related virus, hindering a black and white 
threshold for percentage and depth of coverage. Overall, a horizontal 
genome coverage of at least three distinct genome regions aligned after 
background subtraction based on negative controls is recommended 
[25,40] (Recommendation 19). 
5.1. Analytical sensitivity, specificity and limit of detection (LOD) 
For a fair comparison of mHTS with conventional routine testing, the 
performance can only be analyzed in cases where a respective conven-
tional test (same viral target/direct detection method/similar time 
point) was performed on the same, fresh or defrosted, sample [54]. This 
shows the inherent difficulty of validating such a broad test that can 
theoretically detect any pathogen in a given sample. This is aggravated 
by the fact that in many clinical scenarios (e.g. meningitis/encephalitis) 
reference standards are missing. For instance, when comparing results to 
a non-reference standard, the US FDA recommends in their statistical 
guidance on reporting results from studies evaluating diagnostic tests, to 
assess sensitivity and specificity as positive and negative percent 
agreement, respectively (www.fda.gov/downloads/medicaldevices/ 
deviceregulationandguidance/guidancedocuments/ucm071287.pdf). 
Spiked samples or well-characterized samples with known copy 
numbers of viruses are used to establish sensitivity for a “core” set of the 
target viruses. LOD can be determined by analyzing serial dilutions of a 
clinical sample containing a known, quantified pathogen subjected to 
mHTS, or using a set of calibrated internal controls [40]. Cultured virus 
is not recommended for LOD testing, as cultured viruses may not 
represent viruses or viral nucleic acid in clinical samples (e.g. herpes-
viruses [32]). To determine the LOD, cut-off thresholds need to be 
defined on coverage and sequence depth that are used in decision 
making always in the context of sample composition (e.g. white blood 
cell count, grams of tissue), because host nucleic acid burden can quickly 
change this LOD. The number of pathogen reads can be normalized to 
those obtained from internal standards [40] and validation data can be 
obtained by comparing to PCR results using samples with prototype 
pathogens (e.g. DNA and RNA viruses, double-stranded and 
single-stranded viruses, circular and linear, enveloped and 
non-enveloped viruses) (Recommendation 19). 
5.2. Proficiency testing and external quality assessment (EQA) 
EQA of mHTS methods for viral pathogen detection may address the 
following qualitative characteristics: i) correct pathogen detection at the 
species level or deeper, ii) quantitative characteristics (e.g. target read 
numbers) and iii) logistic performance (turn-around-time within a 
clinically relevant time frame) (Recommendation 20). QCMD (www. 
qcmd.org) aims to launch a viral mHTS metagenomics EQA program 
by the end of 2020, unaccredited interlaboratory exchange for EQA is 
second best in complying to the guidelines. Implementation of mHTS in 
ISO1589 accredited laboratories and the upcoming new in vitro di-
agnostics regulation raises several questions on for example the exten-
sity of the validation when considering all possible targets. These 
regulations may result in more frequent and extensive assessment of 
mHTS protocols both by manufacturers and diagnostic laboratories, 
potentially leading to more standardization of mHTS protocols, valida-
tion requirements, and performance characteristics. Some manufac-
turers of mHTS library preparation kits and software have requested CE- 
IVD marking restricted to a limited panel of pathogens that has been 
validated and compared with conventional, usually molecular assays. 
Questions are raised when considering the assay performance of 
detecting micro-organisms that are less easily compared with conven-
tional diagnostic methods, such as cultivation, or because the micro- 
organism is not tested for at all conventionally, such as the entire pop-
ulation of viruses present in a particular sample, the virome. The above 
described recommendation on the use of prototype viruses may be a 
practical consideration (see Recommendation 19). 
6. Ethical considerations 
When an assay is launched for clinical use, medically important and 
unimportant findings, as well as findings putatively important have to 
be considered. Along with accumulating data from research, currently 
irrelevant findings may become relevant in the future, e.g. if a new 
disease association is established or if a new drug launched on the 
market. Thus, storing all sequence information for future use may be 
justified however subject to (inter)national legislation and is outside the 
Table 3 
External providers for viral/pathogen metagenomics commercial assays (wet lab). RUO; research use only.  
Service offered Provider Test Sample Certified Website Citation 
Sample referral 
Karius Karius test Blood CLIA lab www.kariusdx.com [48] 
Pathoquest iDTECTTM Dx Blood CE-IVD www.pathoquest.com [47] 
IDbyDNA Explify Platform Respiratory Any (RUO) CLIA lab www.idbydna.com [44] 
Library preparation reagents and bioinformatics ARC-BIO GallileoTM Pathogen Solution Blood (Plasma) RUO www.arcbio.com [42]  
F.X. López-Labrador et al.                                                                                                                                                                                                                    
Journal of Clinical Virology 134 (2021) 104691
7
scope of the current manuscript. 
With a potent method such as mHTS, incidental microbiological 
findings are to be expected up-front. The clinician has to be aware of 
such a possibility and has to be prepared to explain the impact of such 
findings to the patient. Some findings may be unrelated to the patient’s 
illness but may be significant for their health (e.g. finding an unexpected 
HIV, HBV or HCV infection). How to deal with such findings should be 
properly documented before launching an mHTS assay. However, sto-
chastic findings should not unnecessarily complicate result interpreta-
tion. How to proceed with sequence reads of human host background 
has to be considered as well, as they contain even more sensitive in-
formation, and this will be addressed in Part II of the Recommendations. 
With nanopore technology’s, selectively excluding sequencing of human 
background DNA reads could be an option [55]. 
7. Conclusions 
For some clinical syndromes, such as encephalitis, there is a need to 
extend the diagnostic portfolio with mHTS. For many others, due to the 
cost and turn-around-time constraints, none of the currently available 
mHTS methods seem capable of completely replacing conventional 
diagnostic testing in the near future. Nonetheless, the recommendations 
provided here are intended to guide laboratories on the implementation 
of mHTS for Clinical and Public Health Virology diagnostic workflows. 
Technical, procedural and financial parameters will develop rapidly, 
and it is anticipated that these future developments will support the 
progressive and broad introduction of metagenomic sequencing into 
Clinical and Public Health diagnostic laboratories. 
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next-generation sequencingâ€“Based oncology panels: a joint consensus 
recommendation of the association for molecular pathology and college of 
american pathologists, J. Mol. Diagn. 19 (3) (2017) 341–365. 
[43] R. Schlaberg, K. Queen, K. Simmon, K. Tardif, C. Stockmann, S. Flygare, 
B. Kennedy, K. Voelkerding, A. Bramley, J. Zhang, et al., Viral pathogen detection 
by metagenomics and pan-viral group polymerase chain reaction in children with 
pneumonia lacking identifiable etiology, J. Infect. Dis. 215 (9) (2017) 1407–1415. 
[44] R. Schlaberg, C.Y. Chiu, S. Miller, G.W. Procop, G. Weinstock, Validation of 
metagenomic next-generation sequencing tests for universal pathogen detection, 
Arch. Pathol. Lab. Med. 141 (6) (2017) 776–786. 
[45] P. Parize, E. Muth, C. Richaud, M. Gratigny, B. Pilmis, A. Lamamy, J.-L. Mainardi, 
J. Cheval, L. de Visser, F. Jagorel, et al., Untargeted next-generation sequencing- 
based first-line diagnosis of infection in immunocompromised adults: a 
multicentre, blinded, prospective study, Clin. Microbiol. Infect. (2017). 
[46] T.A. Blauwkamp, S. Thair, M.J. Rosen, L. Blair, M.S. Lindner, I.D. Vilfan, T. Kawli, 
F.C. Christians, S. Venkatasubrahmanyam, G.D. Wall, et al., Analytical and clinical 
validation of a microbial cell-free DNA sequencing test for infectious disease, Nat. 
Microbiol. 4 (4) (2019) 663–674. 
[47] E.T. Mee, M.D. Preston, P.D. Minor, S. Schepelmann, Development of a candidate 
reference material for adventitious virus detection in vaccine and biologicals 
manufacturing by deep sequencing, Vaccine 34 (17) (2016) 2035–2043. 
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